{
    "organizations": [],
    "uuid": "c58d0d5d71214bb85ae0f28ea9e7fac372f8d9db",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sumitomo-dainippon-pharma-and-jcr/brief-sumitomo-dainippon-pharma-and-jcr-pharmaceuticals-sign-license-agreement-idUSL4N1QG2S4",
    "ord_in_thread": 0,
    "title": "BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26(Reuters) - Sumitomo Dainippon Pharma Co Ltd\n* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases\nSource text in Japanese: goo.gl/akBwrg\nFurther company coverage: (Beijing Headline News)\n ",
    "published": "2018-02-26T15:17:00.000+02:00",
    "crawled": "2018-02-27T14:49:48.086+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "sumitomo",
        "dainippon",
        "pharma",
        "co",
        "ltd",
        "say",
        "jcr",
        "pharmaceutical",
        "co",
        "ltd",
        "signed",
        "license",
        "agreement",
        "barrier",
        "penetration",
        "technology",
        "creation",
        "therapeutic",
        "agent",
        "central",
        "nervous",
        "system",
        "disease",
        "source",
        "text",
        "japanese",
        "company",
        "coverage",
        "beijing",
        "headline",
        "news"
    ]
}